CD38 and Miyoshi myopathy: Eicher et al. conducted an in vitro study in which they investigated whether lenalidomide improves the anti-MM activity of myeloma-associated macrophages (MAMs) elicited by MOR202 (monoclonal antibody against CD38) and whether the vitamin D pathway is part of its modulatory effects.